Featured
Platform
ArcheNova's proprietary technology platforms form the scientific foundation
of our biopharmaceutical value creation model
MSC-Derived Exosome Therapeutics
ArcheNova's wholly owned subsidiary is dedicated to the development, clinical translation, and commercialization of MSC-derived exosome therapeutics.
Built on over 20 years of internationally recognized research, our proprietary Extracellular Vesicle (EV) Platform is designed to develop scalable cell-free biologics for global healthcare.
Therapeutic Focus
Our platform technologies support the development of innovative therapies across multiple disease areas.
Regenerative
Medicine
Inflammatory
Diseases
Ophthalmology
Orthopaedics
Neurodegenerative Diseases
PLATFORM 02
Immortalized MSC Platform
Our proprietary Immortalized MSC Platform provides a stable, renewable, and standardized cell source for the consistent production of clinical-grade exosomes.
Compared with primary MSCs, our platform offers:
Consistent Manufacturing
Standardized production with high batch-to-batch consistency.
Scalable Manufacturing
Supporting clinical development through commercial-scale production.
Reliable
Cell Banking
MCB and WCB systems ensure traceability and quality.
Global Development Ready
Designed to support GMP manufacturing, clinical studies, and global regulatory requirements.